Parkinson's disease (PD) is a degenerative disorder of the brain characterized by the
impairment of the nigrostriatal system. This impairment leads to specific motor …

The complexity and costs associated with traditional randomized, controlled trials have
increased exponentially over time, and now threaten to stifle the development of new drugs …

Background: The emergence of new technologies measuring outcomes in Parkinson's
disease (PD) to complement the existing clinical rating scales has introduced the possibility …

Parkinson's disease (PD) is characterized by a variety of motor and non-motor symptoms. As
disease progresses, fluctuations in the response to levodopa treatment may develop, along …

Measurement of disease state is essential in both clinical practice and research in order to
assess the severity and progression of a patient's disease status, effect of treatment, and …

Introduction There is an ongoing digital revolution in the field of Parkinson's disease (PD) for
the objective measurement of motor aspects, to be used in clinical trials and possibly …

Parkinson's disease (PD) is affecting about 1.2 million patients in Europe with a prevalence
that is expected to have an exponential increment, in the next decades. This epidemiological …

Introduction: The burden of non-motor symptoms (NMS) is a major determinant of health-
related quality of life in Parkinson's disease (PD), particularly at its late stage. Areas covered …

Background: The MDS-UPDRS (Movement Disorders Society–Unified Parkinson's Disease
Rating Scale) is the most widely used scale for rating impairment in PD. Subscores …

Background: Wearable sensors provide accurate, continuous objective measurements,
quantifying the variable motor states of patients with Parkinson's disease (PD) in real time …